Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 7, 2010

View Archived Issues

LMV-601 is potently active against HSV and HPV in preclinical studies

Neutrophil elastase inhibitor AZD-9668 shows promise in COPD

Tuberculosis candidate PNU-100480 is well tolerated in healthy volunteers

Pfizer discloses new activators of glucokinase

FDA provides guidance to Celsion for ThermoDox NDA

SNPs in PIK3C2B gene correlate with risk of Parkinson's disease

B-27-PD enters phase I/II trial in chronic noninfectious uveitis

BioRelix and Merck & Co. subsidiary partner to identify antibacterial drug candidates

Artemether sublingual spray is safe and efficacious in children with severe malaria

Cosmo Pharma's CB-03-01 effective in proof-of-concept alopecia study

FDA orphan drug status for rozrolimupab in immune thrombocytopenia

FDA grants orphan drug status to Prolor's longer-acting human growth hormone

Viralytics advances phase I trial of coxsackievirus A21

Bionomics receives approval for two phase Ib trials of BNC-210 in France

Meda completes acquisition of Alaven

Daiichi Sankyo discovers new PPAR-gamma agonists

Starpharma and Lilly collaborate on dendrimer-drug conjugate development

UCB patents new inhibitors of PI3K isoforms

U.S. researchers claim new DNA topoisomerase 1 inhibitors

Flu vaccine LIQ-001 advances to clinic in phase I trial

Phase III trial of aripiprazole in schizophrenia meets efficacy criteria

Akebia Therapeutics presents data from phase IIa AKB-6548 trial

Japanese scientists disclose new diagnostics for Alzheimer's disease

Altravax receives NIH grants for research on vaccines for HIV-1

Johnson & Johnson to acquire all outstanding shares of Crucell

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...